Literature DB >> 33288648

Establishment and Validation of Pathogenic CS17+ and CS19+ Enterotoxigenic Escherichia coli Challenge Models in the New World Primate Aotus nancymaae.

Eric R Hall1, Aisling O'Dowd2,3, Julianne E Rollenhagen2,3, Nereyda Espinoza4, Gladys Nunez4, Stephen J Savarino3,5.   

Abstract

Enterotoxigenic Escherichia coli (ETEC) is a common cause of diarrheal illness in the military, travelers, and children living in low- to middle-income countries. Increased antibiotic resistance, the absence of a licensed vaccine, and the lack of broadly practical therapeutics perpetuate the significant health and financial burden resulting from ETEC infection. A critical step in the evaluation of vaccines and therapeutics is preclinical screening in a relevant animal disease model that closely replicates human disease. We previously developed a diarrheal model of class 5a colonization factor (CF) CFA/I-expressing ETEC in the New World owl monkey species Aotus nancymaae using ETEC strain H10407. In order to broaden the use of the model, we report here on the development of A. nancymaae models of ETEC expressing the class 5b CFs CS17 and CS19 with strains LSN03-016011/A and WS0115A, respectively. For both models, we observed diarrheal attack rates of ≥80% after oral inoculation with 5 × 1011 CFU of bacteria. These models will aid in assessing the efficacy of future ETEC vaccine candidates and therapeutics.

Entities:  

Keywords:  CS17; CS19; enterotoxigenic Escherichia coli; nonhuman primates; vaccine

Year:  2021        PMID: 33288648      PMCID: PMC8097270          DOI: 10.1128/IAI.00479-20

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

Review 1.  Colonization factors of human enterotoxigenic Escherichia coli (ETEC).

Authors:  W Gaastra; A M Svennerholm
Journal:  Trends Microbiol       Date:  1996-11       Impact factor: 17.079

Review 2.  A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC).

Authors:  Chad K Porter; Mark S Riddle; David R Tribble; A Louis Bougeois; Robin McKenzie; Sandra D Isidean; Peter Sebeny; Stephen J Savarino
Journal:  Vaccine       Date:  2011-05-25       Impact factor: 3.641

3.  Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome.

Authors:  Eric D Shah; Mark S Riddle; Christopher Chang; Mark Pimentel
Journal:  J Neurogastroenterol Motil       Date:  2012-04-09       Impact factor: 4.924

4.  Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19.

Authors:  Robin McKenzie; Chad K Porter; Joyce A Cantrell; Barbara Denearing; Aisling O'Dowd; Shannon L Grahek; Stephanie A Sincock; Colleen Woods; Peter Sebeny; David A Sack; David R Tribble; A Louis Bourgeois; Stephen J Savarino
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

5.  Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli.

Authors:  T S Coster; M K Wolf; E R Hall; F J Cassels; D N Taylor; C T Liu; F C Trespalacios; A DeLorimier; D R Angleberger; C E McQueen
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

6.  Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.

Authors:  Karen L Kotloff; James P Nataro; William C Blackwelder; Dilruba Nasrin; Tamer H Farag; Sandra Panchalingam; Yukun Wu; Samba O Sow; Dipika Sur; Robert F Breiman; Abu Sg Faruque; Anita Km Zaidi; Debasish Saha; Pedro L Alonso; Boubou Tamboura; Doh Sanogo; Uma Onwuchekwa; Byomkesh Manna; Thandavarayan Ramamurthy; Suman Kanungo; John B Ochieng; Richard Omore; Joseph O Oundo; Anowar Hossain; Sumon K Das; Shahnawaz Ahmed; Shahida Qureshi; Farheen Quadri; Richard A Adegbola; Martin Antonio; M Jahangir Hossain; Adebayo Akinsola; Inacio Mandomando; Tacilta Nhampossa; Sozinho Acácio; Kousick Biswas; Ciara E O'Reilly; Eric D Mintz; Lynette Y Berkeley; Khitam Muhsen; Halvor Sommerfelt; Roy M Robins-Browne; Myron M Levine
Journal:  Lancet       Date:  2013-05-14       Impact factor: 79.321

7.  Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

Authors:  Robin McKenzie; A Louis Bourgeois; Sarah A Frech; David C Flyer; Arlene Bloom; Kazem Kazempour; Gregory M Glenn
Journal:  Vaccine       Date:  2007-01-23       Impact factor: 3.641

Review 8.  Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy.

Authors:  Divya Hosangadi; Peter G Smith; Birgitte K Giersing
Journal:  Vaccine       Date:  2017-10-12       Impact factor: 3.641

9.  Characterization of a new putative colonization factor (CS17) from a human enterotoxigenic Escherichia coli of serotype O114:H21 which produces only heat-labile enterotoxin.

Authors:  M M McConnell; M Hibberd; A M Field; H Chart; B Rowe
Journal:  J Infect Dis       Date:  1990-02       Impact factor: 5.226

10.  Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.

Authors:  Firdausi Qadri; Marjahan Akhtar; Taufiqur R Bhuiyan; Mohiul I Chowdhury; Tasnuva Ahmed; Tanzeem A Rafique; Arifuzzaman Khan; Sadia I A Rahman; Farhana Khanam; Anna Lundgren; Gudrun Wiklund; Joanna Kaim; Madeleine Löfstrand; Nils Carlin; A Louis Bourgeois; Nicole Maier; Alan Fix; Thomas Wierzba; Richard I Walker; Ann-Mari Svennerholm
Journal:  Lancet Infect Dis       Date:  2019-11-19       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.